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Introduction: Mesenchymal stem cells (MSCs) are adult multipotent stem cells that possess regenerative and
immunomodulatory properties. They have been widely investigated as therapeutic agents for a variety of disease
conditions, including tissue repair, inflammation, autoimmunity, and organ transplantation. Importantly, systemically
infused MSCs selectively home to primary and metastatic tumors, though the molecular mechanisms of tumor
tropism of MSCs remain incompletely understood. We have exploited the active and selective MSCs homing to
cancer microenvironments to develop a rapid and selective blood test for the presence of cancer.
Methods: We tested the concept of using transplanted MSCs as the basis for a simple cancer blood test. MSCs
were engineered to express humanized Gaussia luciferase (hGluc). In a minimally invasive fashion, hGluc secreted
by MSCs into circulation as a reporter for cancer presence, was assayed to probe whether MSCs co-localize with
and persist in cancerous tissue.
Results: In vitro, hGluc secreted by engineered MSCs was detected stably over a period of days in the presence
of serum. In vivo imaging showed that MSCs homed to breast cancer lung metastases and persisted longer in
tumor-bearing mice than in tumor-free mice (P < 0.05). hGluc activity in blood of tumor-bearing mice was
significantly higher than in their tumor-free counterparts (P < 0.05).
Conclusions: Both in vitro and in vivo data show that MSCs expressing hGluc can identify and report small
tumors or metastases in a simple blood test format. Our novel and simple stem cell-based blood test can
potentially be used to screen, detect, and monitor cancer and metastasis at early stages and during treatment.Introduction
Cancer is a leading cause of human morbidity and mor-
tality, and its origins, biomarkers, and detection remain
difficult to pinpoint [1]. Although early detection has
proven to be a useful and often necessary first step to
effectively manage and treat cancer [2], it remains a
challenge at early stages to identify cancer, especially
small tumors and metastases which account for over
90 % of cancer mortality [3, 4]. Methods of cancer detec-
tion based on imaging are non-invasive, but common* Correspondence: weianz@uci.edu
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and the use of potentially irritating contrast agents [2]. For
instance, positron emission tomography (PET), computed
tomography (CT), and their combinations (PET-CT) are
widely used for identifying and staging tumors but require
high doses of ionizing radiation and have limited specifi-
city and resolution [5]. Other imaging modalities, such as
magnetic resonance imaging (MRI) and ultrasound, do
not use radiation but are still unable to achieve spatial
resolution smaller than several millimeters [6, 7]. On the
other hand, tissue biopsies are invasive and suffer from
false negatives for heterogeneous tumors, and obtaining
biopsies from multiple small disseminated tumors (e.g.,
metastases) is impractical. Cancer screening also uses tests
for biomarkers, including circulating tumor cells, exo-
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composed of mass-encoded peptides that can be released
upon tumor protease cleavage and then detected in
urine [8, 9]. Such approaches, however, still rely on passive
delivery of nanoparticles to tumors via the enhanced per-
meability and retention (EPR) effect and on limited types of
endogenous proteins, both of which are cancer type-
specific. More recently, scientists have also reported a pro-
biotic microbe-based system to deliver synthetic biomarker
for cancer detection in urine [10]. Nevertheless, cancer bio-
marker discovery has led to only a few biomarkers used in
clinical diagnosis since cancer biomarkers frequently suffer
from low sensitivity and specificity [11].In particular, cancer heterogeneity and evolution make
it challenging to rely on molecular biomarkers for cancer
detection [1]. For example, the commonly used cancer
biomarkers prostate-specific antigen for prostate cancer
and BRCA1/2 gene mutations for breast cancer can
identify only about 25 % and 10 % to 25 % of the pa-
tients in each cancer type, respectively [12]. Indeed, it
has been widely accepted that a single biomarker typic-
ally lacks the sensitivity and specificity that are necessary
for useful diagnosis. Intriguingly, recent research indi-
cates that most cancers are caused by stochastic events
rather than predictable mutations [13]. Thus, finding
biomarkers that recognize multiple types of cancers with
no common genetic basis is likely less promising than
previously thought. In summary, there is clearly an unmet
clinical need for sensitive early-stage cancer and metasta-
sis tests that can “universally” identify many types of can-
cers independently of specific biomarkers from healthy
controls and other conditions that share similar symptoms
(e.g., inflammation) as well as to discriminate different
(sub)types of cancers at different stages.
Cells, including immune and stem cells, act as autono-
mous and adaptive agents and these properties have re-
cently been used for cancer treatment and drug delivery
[14–17]. In particular, mesenchymal stem (or stromal)
cells (MSCs) have been tested as therapeutic agents be-
cause of their intrinsic regenerative and immunomodula-
tory features [18–23]. MSCs are under investigation for
treating a wide array of diseases, including diabetes,
myocardial infarction, stroke, and autoimmune diseases
[24–26]. MSCs are also the world’s first manufactured
stem cell product to receive clinical approval (i.e., Pro-
chymal manufactured by Osiris (Columbia, MD, USA)
was approved in Canada to treat graft-versus-host dis-
ease) [26], suggesting that they may be a safe source
for diagnostic and therapeutic uses in humans. Im-
portantly, systemically infused MSCs preferentially
home to and integrate with tumors, including both
primary tumors and metastases in different anatomical
locations [24]. As we have recently reviewed [22],
mounting evidence now suggests that MSCs possess
leukocyte-like, active homing mechanisms for tumor
tropism involving a variety of adhesion molecules (e.g.,
P-selectin and vascular cell adhesion molecule-1) and
tumor-derived cytokines, chemokines, and growth fac-
tors (e.g., CXCL12 and platelet-derived growth factor).
This selective and active homing ability makes MSCs
appealing vectors for localized delivery of therapeutics
to treat cancers, including gliomas, melanomas, breast
cancer, and lung metastases, in ongoing clinical trials
[15, 24]. In addition, MSCs engineered with probes
(such as luciferase) have been used to detect and image
tumors in situ [19, 27]. However, imaging methods such
as PET/single-photon emission computed tomography
Scheme 1 Using engineered mesenchymal stem cells (MSCs) to detect cancer. Engineered MSCs (gray) secreting humanized Gaussia luciferase
(hGluc) (green) are systemically administered into patients with cancer (breast cancer lung metastasis in this case). Engineered MSCs home to
tumor (cyan) niche and persist, secreting hGluc into blood. Then patient blood can be collected and hGluc activity measured
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infusion are limited by the same aforementioned disadvan-
tages of cancer detection [2].
In this article, we present the concept of using exogen-
ous MSCs as the basis for a simple cancer blood test
(Scheme 1). Here, we hypothesize that, owing to their
tumor tropism property, MSCs engineered with a se-
creted reporter can actively and specifically home to
tumor sites regardless of the type and location of the
tumors and persist there longer compared with MSCs in
healthy microenvironments. MSCs engineered to express
humanized Gaussia luciferase (hGluc) [28–31] were sys-
temically administered to mice harboring breast cancer
cells, exhibited tumor tropism and persistence, andsecreted hGluc into the bloodstream of tumor-bearing
mice. Thus, MSCs engineered with secreted reporters
can potentially be developed into a blood test for broad
cancer screening and monitoring.
Methods
Cell lines and cell culture
Human bone marrow MSCs were obtained from the
Texas A&M Health Science Center and were expanded
to within passages 3–6. The cells were routinely main-
tained in minimum essential medium alpha (MEMα)
(Life Technologies, Carlsbad, CA, USA) supplemented
with 15 % fetal bovine serum (FBS) (Atlanta Biologicals,
Norcross, GA, USA) and 1 % penicillin-streptomycin
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humidified incubator containing 5 % CO2. The human
breast cancer cell line MDA-MB-231 was obtained from
American Type Culture Collection (ATCC) (Manassas,
VA, USA). These cells were grown in Leibovitz’s L-15
medium containing L-glutamine (Corning, Corning, NY,
USA) and supplemented with 10 % FBS and 1 U/ml
PenStrep at 37 °C in a humidified incubator without
CO2. The human colon cancer cell line LoVo was ob-
tained from ATCC. These cells were grown in Kaighn’s
Modification of Ham’s F-12 Medium (F-12 K; ATCC)
and supplemented with 10 % FBS and 1 U/ml PenStrep
at 37 °C in a humidified incubator with 5 % CO2. The
293 T-LV cell line (GenTarget, San Diego, CA, USA) was
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Life Technologies) supplemented with 15 % FBS, non-
essential amino acid (NEAA) (1X, 100 U/ml; Life Tech-
nologies), and 1 U/ml PenStrep at 37 °C in a humidified
incubator containing 5 % CO2. All the cell experiments
and procedures were performed after the approval from
the University of California, Irvine (UCI) Institutional Bio-
safety Committee (protocol number 2012–1412).
Generation of lentiviral vectors
The following lentiviral (LV) vectors were used in this
study: LV-eGFP, LV-Fluc-tdT, and LV-hGluc. The se-
quences of interest from pUCBB-eGFP (#32548; Addgene,
Cambridge, MA, USA), pcDNA3.1(+)/Luc2=tdT (#32904;
Addgene), and pSV40-Gluc (New England BioLabs,
Ipswich, MA, USA) were cloned into the promoterless
LV transfer vector LV-PL4 (GenTarget).
Lentiviral transduction
All LV constructs were packaged (pMD2.G, #12259; pRSV-
Rev, #12253; pMDLg/pRRE, #12251; all from Addgene) as
LV vectors in 293 T-LV cells [32] by using Lipofectamine
LTX and PLUS™ Reagents (Life Technologies). MSCs and
breast cancer cells were transduced with LVs by incubating
virions in a culture medium containing 100 μg/ml protam-
ine sulfate (Sigma-Aldrich, St. Louis, MO, USA). After
selection with medium containing 10 μg/ml Puromycin
(MP Biomedicals, Santa Ana, CA, USA), cells were visual-
ized for fluorescent protein expression by using fluores-
cence microscopy.
In vitro bioluminescence assays
LV-Fluc-tdT MSCs (Fluc-tdT-MSCs) expressing firefly lu-
ciferase (Fluc) or LV-hGluc MSCs (hGluc-MSCs) express-
ing humanized Gaussia luciferase (hGluc) were seeded in
serially diluted concentrations. After the cells were washed
with PBS (Lonza, Basel, Switzerland), luciferase substrates
(150 μg/ml D-luciferin for Fluc, PerkinElmer, Waltham,
MA, USA, or 20 μM coelenterazine (CTZ) for hGluc,
NanoLight Technologies, Pinetop, AZ, USA) were addedand the activities of Fluc and hGluc were imaged as previ-
ously described [33]. Conditioned medium (CM) of
hGluc-MSCs was harvested and filtered. CM (5 μl) was
then mixed with human serum (Atlanta Biologicals) with
or without PBS dilution to final serum concentrations of
0 %, 5 %, 50 %, or 100 %, incubated at 37 °C at various
times as indicated, and hGluc activity was measured with
20 μM CTZ (final concentration in a final volume of
200 μl). Mouse blood was collected as described [34] and
added into ¼ volume of EDTA (Sigma-Aldrich) solution
(50 mM, pH=8.0). Blood (5 μl) was mixed with 100 μl of
100 μM CTZ, and hGluc activity was measured immedi-
ately. All bioluminescent assays were performed with an
IVIS Lumina (Caliper LifeSciences, Hopkinton, MA, USA)
or a plate reader (BioTek, Winooski, VT, USA). All sam-
ples above were measured in triplicate.
Cell implantation and imaging in vivo
LV-Fluc-tdT MDA-MB-231 (Fluc-tdT-231) or LV-eGFP
MDA-MB-231 (eGFP-231) breast cancer cells or LoVo
colon cancer cells (0.5×106 ; 2.5×106/ml in DPBS)
were implanted intravenously (i.v.) into nonobese
diabetic/severe combined immunodeficiency gamma
(NSG) mice (5 weeks, #005557; The Jackson Laboratory,
Bar Harbor, ME, USA). Five weeks later, in vivo Fluc ac-
tivity from Fluc-tdT-231 cells was measured as described
[35]. Briefly, in vivo Fluc signal was imaged with IVIS
Lumina 10 minutes after intraperitoneal (i.p.) injection
of D-luciferin (150 mg/kg in DPBS; Lonza) into mice.
hGluc-MSCs or Fluc-tdT-MSCs (106; 5×106/ml in
DPBS) were systemically infused into the mice harboring
breast cancer cells and into healthy control mice. hGluc-
MSCs were labeled with the Dil lipophilic dye (5 μl/106
cells; Life Technologies) by incubation at 37 °C for 20 mi-
nutes before infusion. Mice were anesthetized with
2~3 % of isoflurane (Western Medical Supply, Arcadia,
CA, USA), and in vivo Fluc activity was measured at the
indicated time points. Imaging was performed with the
IVIS Lumina (n=4 in each case). All animal experiments
and procedures were performed after the approval from
the UCI Institution of Animal Care and Use Committee
(protocol number 2012–3062) and conducted according
to the Animal Welfare Assurance (#A3416.01).
Tissue processing and immunohistochemistry
Tissues were collected and flash frozen in Tissue-Tek
O.C.T™ Compound (Sakura Finetek, Torrance, CA,
USA), with or without overnight fixation in 4 % parafor-
maldehyde (Amresco, Solon, OH, USA), and with over-
night incubation in 30 % sucrose solution (Amresco).
Sections 8 μm thick were taken by cryostat and stained
following an immunohistochemistry protocol for eGFP
(sheep polyclonal IgG; Pierce Biotechnology, Rockford,
IL, USA) and Fluc (rabbit polyclonal IgG; Abcam,
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(Thermo Fisher Scientific, Waltham, MA, USA) at −20 °
C for 10 minutes, permeabilized in 0.1 % Triton X-100
(Sigma-Aldrich) for 10 minutes, and blocked in 0.1 %
Triton X-100 with 5 % normal donkey serum (Sigma-
Aldrich) for 30 minutes. Primary antibodies were di-
luted 1:100 from the stock solution in 0.05 % Tween-20
(Sigma-Aldrich) in PBS and applied overnight at 4 °C.
Slides were washed in 1X PBS, and then secondary anti-
bodies (donkey anti-sheep IgG conjugated to Alexa
Fluor 488, donkey anti-rabbit IgG conjugated to Alexa
Fluor 594, Jackson ImmunoResearch Laboratories, West
Grove, PA, USA) were diluted 1:500 from the stock
solution in 0.05 % Tween-20 in PBS and applied for
30 minutes at room temperature. TOTO-3 Iodide
(2.4 μM; Life Technologies) was added to the secondary
antibody incubation. DAPI (4',6-diamidino-2-phenylin-
dole) (50 μg/ml; Life Technologies) in PBS was applied
to slides for 10 minutes before mounting. Slides were
washed in PBS and mounted with DPX (Di-N-butyle
phthalate in xylene) (Sigma-Aldrich) or Fluoromount-G
(SouthernBiotech, Birmingham, AL, USA).Fig. 1 Humanized Gaussia luciferase (hGluc) is secreted in vitro and is stabl
luciferase (hGluc-MSC) and native MSCs (N-MSCs) were seeded onto 96-we
was harvested. The hGluc substrate coelenterazine (CTZ) was added with a
by using a plate reader (absorbance at wavelengths of 300-700 nm, exposu
PBS, and CTZ was added at a final concentration of 20 μM. hGluc activity w
minimum = 6.64×108, maximum = 8.93×109. c CM of hGluc-MSCs was harv
24 hours at 37 °C. A final concentration of 20 μM of CTZ was added, and h
activity was detectable in 100 % serum. ****P < 0.0001. Error bar: mean ± sStatistical analysis
Data were analyzed by Student’s t test when comparing
two groups and by analysis of variance when comparing
more than two groups. Data were expressed as mean ±
standard deviation or as mean ± standard error of the
mean, and differences were considered significant at
P values of less than 0.05.
Results
Humanized Gaussia luciferase is secreted from engineered
MSCs in vitro and is stable and detectable in blood
Human bone marrow MSCs were stably transduced with
lentivirus to express secreted humanized Gaussia lucifer-
ase (hGluc) as described above. To determine whether
hGluc is secreted in an active form by MSC, cell-free
CM was harvested from hGluc-MSCs 24 hours after
MSC seeding at different concentrations (100, 1000,
2500, or 5000 cells per cm2). The substrate CTZ was
added and hGluc activity was measured for both cells
and CM (Fig. 1a). hGluc activity increased with increas-
ing cell number (Fig. 1a). In addition, hGluc activity in
CM was 3- to 6-fold higher than inside cells (Fig. 1a),e in blood. a Mesenchymal stem cells expressing humanized Gaussia
ll plates. Twenty-four hours later, cell-free conditioned medium (CM)
final concentration of 20 μM. hGluc activity was measured immediately
re time = 2 s). b Serial dilution of hGluc-MSC CM was performed in
as measured with an IVIS Lumina (exposure time = 0.5 s). Color scale:
ested and incubated with human serum for 10 minutes and 2, 8, or
Gluc activity was measured immediately (exposure time = 2 s). hGluc
tandard deviation. A.U. arbitrary units, PBS phosphate-buffered saline
Fig. 2 Human-derived breast cancer was observed in xenotransplantation murine model. a Five weeks after 0.5×106 Fluc-tdT-231 were seeded
i.v., NSG mice were injected intraperitoneally with D-Luciferin (150 mg/kg in Dulbecco’s PBS) and in vivo Fluc activity was measured with IVIS
Lumina 10 minutes after substrate administration. Exposure time = 5 s. Color scale: minimum = 5.13×107, maximum = 2.46×108. b Representative
pictures of tumor-free (left) and tumor-bearing (right) lungs. Eight weeks after MDA-MB-231 breast cancer cells or PBS were seeded i.v., NSG mice
were euthanized and lungs were harvested. Frozen sections of lungs of c tumor-free mice and d eGFP-231 tumor-bearing mice sacrificed 5 weeks
after cancer seeding were stained with anti-eGFP (green), anti-Ki67 (blue), and TOTO-3 (red). Scale bar: 50 μm. eGFP enhanced green fluorescent
protein, i.v. intravenously, NSG nonobese diabetic/severe combined immunodeficiency gamma, PBS phosphate-buffered saline
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secreted in active form, as expected. hGluc-MSC CM
was serially diluted with PBS and hGluc activity was
measured in vitro and found to exhibit a linear function
of concentration, in agreement with earlier reports [33,
36, 37] (Fig. 1b). To demonstrate whether luciferase ac-
tivity from hGluc-MSCs is detectable and sufficiently
stable in blood, human serum either directly (100 %) or
serially diluted in PBS was mixed with hGluc-MSCs CM.
hGluc activity remained detectable (P < 0.0001) after
24 hours co-incubation and was not decreased signifi-
cantly over time (Fig. 1c), indicating that hGluc-MSCs
can be a stable marker in blood assays in vitro.
Finally, since both firefly luciferase (Fluc-tdT) andhGluc would be used in vivo (below), any potential
cross-reactivity between Fluc-tdT and hGluc-MSCs
was measured (Additional file 1: Figure S1). These two
luciferases were substrate-specific and no cross-reaction
was observed, as reported. Overall, these data show that
hGluc expressed by engineered MSCs is secreted in vitro,
is stable in human serum for up to 24 hours, and exhibits
substrate-specific enzyme activity.
Engineered MSCs home to tumor sites and persist longer
in the lungs of the tumor-bearing mice
As MSCs are reported to naturally home to tumor sites
[18, 19], we tested this phenomenon in our experiment
as a preliminary step to using MSCs that secrete hGluc
Fig. 3 Mesenchymal stem cells home to tumor site and persist longer than in healthy mice. a Five weeks after eGFP-231 were seeded intravenously
into NSG mice, 106 Fluc-tdT-MSCs were administered systemically into both tumor-free (top) and tumor-bearing (bottom) mice. Then mice were
injected intraperitoneally with D-Luciferin (150 mg/kg in Dulbecco’s phosphate-buffered saline), and in vivo Fluc activity was measured at different time
points (2, 6, 24, and 48 hours and 7 and 10 days after MSC infusion) by using an IVIS Lumina to begin data acquisition 10 minutes after substrate
administration (exposure time = 60 s; n=4 in each group). MSCs were cleared out faster in tumor-free mice. Color scale: minimum = 6.50×104,
maximum = 7.50×105. Frozen sections of lungs of b tumor-free mice and c eGFP-231 tumor-bearing mice sacrificed 10 days after Fluc-tdT-
MSC infusion were stained with anti-eGFP (green) and anti-Fluc (red) antibodies. MSCs were observed to home to tumor niche. Scale bar:
50 μm. d Fluc activity measured at different time points was quantified and normalized to the time point of 2 hours. Error bar: mean ± standard
error of the mean. *P <0.05. n=4 in each group. eGFP enhanced green fluorescent protein, Fluc firefly luciferase, MSC mesenchymal stem cell, NSG
nonobese diabetic/severe combined immunodeficiency gamma, tdT tdTomato red fluorescent protein
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Human breast cancer-derived MDA-MB 231 cells were
labeled with eGFP or Fluc-tdT and implanted intraven-
ously (i.v.) into immunodeficient NSG mice (Fig. 2) to
establish a simple in vivo mouse model of breast cancer
that has metastasized in the lungs [38, 39]. Tumor mass
was observed in lungs both in vivo (Fig. 2a) and ex vivo
(Fig. 2b, d), whereas no tumor-related signal was seen
in healthy lungs (Fig. 2a, c). Owing to the fact that
hGluc is secreted by MSCs and to its diluted and limited
signal under whole animal imaging conditions with IVIS
Lumina [40] (data not shown), we used MSCs engineered
with intracellular Fluc-tdT [41] for real-time imaging and
localization of MSCs in tumors in situ. Fluc-tdT-MSCswere simultaneously labeled with red fluorescent protein
(RFP) to assess Fluc transduction efficiency and to image
any co-localized MSCs and tumor cells in subsequent
ex vivo immunohistochemistry. Both Fluc activity and
RFP signal from Fluc-tdT-MSCs were observed in vitro
(Additional file 2: Figure S2), demonstrating that engi-
neered MSCs express Fluc (Additional file 2: Figure S2A)
with high transduction efficiency (>90 % RFP+; Additional
file 2: Figure S2B-D).
To investigate any differences in MSCs homing between
cancer-bearing and healthy mice, 106 Fluc-tdT-MSCs were
systemically infused into mice with or without breast
cancer. Mice were anesthetized and in vivo Fluc activity
was measured after i.p. administration of D-luciferin
Fig. 4 Gaussia luciferase (hGluc) is active in murine blood and the signal is elevated in tumor-bearing mice. a Frozen sections of lungs of
tumor-bearing mice sacrificed 10 days after Dil-labeled hGluc-MSC administration were stained with DAPI and then imaged by fluorescence
microscopy. MSCs (red) were observed to home to tumor niche (dense blue). Scale bar: 100 μm. b Five weeks after Fluc-tdT-231 were seeded
intravenously into NSG mice, 106 hGluc-MSCs were administered systemically into both tumor-free and tumor-bearing mice. Then murine
blood was harvested and hGluc activity was measured at different time points (6, 24, and 48 hours and 7 and 10 days after MSC infusion) with
IVIS Lumina immediately after substrate was added. hGluc activity measured at different time points was quantified and normalized to the
time point of 6 hours. The inset graph shows that the hGluc activity in blood between tumor-bearing and tumor-free mice is significantly
different from 48 hours after MSC infusion. Error bar: mean ± standard error of the mean. *P <0.05. Exposure time = 30 s. n=4 in each group.
DAPI 4',6-Diamidino-2-phenylindole, MSC mesenchymal stem cell
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imaging demonstrated that MSCs were detectable in
tumor-bearing mice for as long as 10 days after systemic
administration (Fig. 3a). Ex vivo immunohistochemistry
data confirmed that engineered MSCs homed to the
tumor niche in vivo (Figs. 3c and 4a). As we hypothesized,
engineered MSCs persisted significantly longer intumor-bearing lungs, especially at later time points
(Fig. 3a). We then quantified the Fluc signal and found
that significant differences between tumor-bearing and
tumor-free mice emerged 24 hours after MSC infusion and
lasted until 10 days after infusion (Fig. 3d, n=4, P < 0.05).
To test whether our technology can be applied to other
types of cancer, we investigated fused Fluc-tdT-MSCs into
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were observed (Additional file 3: Figure S3) which dem-
onstrate engineered MSCs could home to and stay in
tumor-bearing lungs for a significantly longer time
compared with tumor-free lungs. Our data, along with
mounting evidence of MSC tumor tropism in the litera-
ture [18, 22, 42, 43], suggest that the in vivo persistence
of engineered MSCs in tumor-bearing compared with
healthy animals provides a viable “marker” for broad
cancer detection.
hGluc secreted by engineered MSCs can be assayed in
the blood of tumor-bearing mice
We next investigated whether MSCs that were engi-
neered to express hGluc can be used to detect metastasis
of breast cancer to the lungs. hGluc was chosen as the
reporter in this study because of its high sensitivity, lack
of nonspecific cross-reactivity to other substrates (e.g.,
Additional file 1: Figure S1), and linear signal over a
wide concentration range (Fig. 1b). In addition, hGluc
has a short half-life in vivo (20 minutes), allowing re-
peated real-time testing without undesirable excessive
signal accumulation, but a long half-life in vitro (6 days),
allowing convenient sample storage [33]. As hGluc is se-
creted, it cannot be used as a marker to co-localize
MSCs and tumor as seen in Fig. 3c for intracellular Fluc.
Therefore, in this set of experiments, we stained hGluc-
MSCs with the Dil lipophilic dye before they were in-
fused i.v. into mice. Like Fluc-tdT-MSCs, Dil-MSCs
were detectable in the tumor niche up to 10 days post-
infusion (Fig. 4a). Mouse blood was collected at the in-
dicated time points, and hGluc activity was measured.
Although the detected signal decayed rapidly over time
as expected, the difference of hGluc activity in blood
between tumor-bearing and tumor-free mice was sig-
nificant starting from 48 hours after MSC administra-
tion and lasting until 10 days post-infusion (Fig. 4b),
suggesting that systemically infused hGluc-MSC can be
used for the potential development of a simple blood
assay for cancer detection in this murine model. In
summary, this set of data supports the feasibility of
using engineered MSCs with secreted hGluc as a blood
test for the presence of cancer.
Discussion
Early detection of cancer, especially metastasis, is a neces-
sary and often critical first step to effectively treat and
eradiate cancer. Traditional imaging tools and molecular
biomarker-based assays are typically complex, expensive,
and/or invasive for routine screening for most cancers;
most importantly, they frequently do not possess the sensi-
tivity and specificity to identify heterogeneous cancers at
early stages. In our study, we developed a stem cell-based
detection system that can detect cancer, includingmetastases, by collecting small amounts of blood with a
minimally invasive procedure. Our engineered MSCs could
home to tumor sites and persist there for significantly lon-
ger durations compared with healthy mice. The signal de-
rived from engineered stem cells lasted longer compared
with current imaging tracers [5], and no repeat administra-
tion was needed. With one single administration, the pres-
ence of tumor could be monitored continuously through a
prolonged period of time, making MSCs a convenient tool
for real-time cancer detection. Compared with acellular
systems (e.g., antibodies and nanoparticles), the natural in-
teractions between MSCs and tumor involve complex
adaptive sensing and responding systems that enable more
efficient and specific reporting of cancer and metastases.
This intrinsic biological property of tumor homing there-
fore potentially allows our stem cell approach to “univer-
sally” identify many cancers regardless of their origins,
types, and anatomical sites. In addition, stem cell-based
probe delivery circumvents many hurdles associated with
passive delivery (i.e., by direct administration or polymeric
nanoparticles via the EPR effect), including penetrating the
endothelium and the increased pressure associated with tu-
mors. In addition, the use of distinct, exogenous markers
(hGluc in this article) as surrogate markers to detect and
monitor cancer is more advantageous than endogenous
markers because of the lack of unique cancer biomarkers.
In our assay, a positive detection of hGluc (even with a
small signal) would indicate the presence of cancer, which
therefore helps to eliminate the need for sophisticated sig-
nal normalization over background as required in conven-
tional cancer detection assays. Therefore, our simple,
noninvasive stem cell-based blood test might be useful for
routine cancer screening, detecting small tumors and me-
tastases, and monitoring cancer progression and recurrence
during the course of treatment.
Since MSCs possess not only tumor tropism but also
tropism for bone marrow and sites of inflammation and in-
jury [20, 23], it remains important to distinguish those con-
ditions from cancer when using MSC-based methods to
detect cancer. In addition, given high cancer heterogeneity,
our next-generation systems aim to engineer MSCs with
activatable, cancer type-specific probes to further increase
the assay specificity. The long-term goal is to establish a
panel of tests that can effectively discriminate between can-
cer (sub)types and stages and distinguish between cancer
and other disorders that share similar symptoms, including
inflammation and injury.
MSCs were chosen in our current (first-generation) sys-
tem because they can be easily obtained from multiple
adult tissues [44], including bone marrow and fat, therefore
avoiding ethical concerns. MSCs are also relatively easy to
expand in culture and can be readily engineered to express
functional therapeutics or reporters [14, 23]. Importantly,
the clinically approved Prochymal and hundreds of other
Note
This article is part of an ‘Emerging Investigators’ collection
showcasing the work of early career investigators who have
demonstrated growing leadership in the field of stem cells and
regenerative medicine. Other articles in the series can be found
online at http://stemcellres.com/series/emerginginvestigators.
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MSCs are generally safe for use in the human without
harsh immunosuppressive regimens. Nonetheless, as MSCs
themselves may participate in cancer progression or regres-
sion [22], further considerations are required. The interac-
tions between MSCs and cancer remain incompletely
understood [14, 22], with different reports indicating con-
flicting findings from endogenous and exogenous MSCs on
cancer progression [22, 45, 46]. Thus, safety tests and opti-
mizations will likely be required to better control the fate of
our engineered MSCs after cancer detection, though no ob-
vious MSC-mediated cancer growth was observed within
our detection window (Additional file 4: Figure S4). To
mitigate this potential issue, for example, a suicide gene
[47] can be engineered into our MSC-based system so that
after completion of the cancer detection test, the
remaining engineered MSCs can be eliminated by using
exogenously administered drugs. For example, indu-
cible human caspase-9 (iC9), which can be activated by
a bio-inert small-molecule drug, has been used as a
safety switch in clinical trials of cell therapy with lim-
ited immunogenicity [48]. Another limitation of our
study is that we used a relatively large tumor burden as
our model to demonstrate our proof-of-concept be-
cause of its technical simplicity. In the future, we will
evaluate our engineered stem cell approach to detect
early-stage cancer and metastases when they are small
by using cancer models with smaller tumor burden by
either reducing the cell number administered or at the
early stages of the beast cancer progression. These
future experiments will allow us to determine the
smallest tumor size we can detect with our technology.
Furthermore, our system may be used as companion
diagnostics combined with other treatments, for example,
identifying certain patients and monitoring side effects.
Finally, our cell-based blood assay may represent a new
platform for monitoring the fate and functions of trans-
planted cells as well as for assessing the in vivo micro-
environment where they reside.
Conclusions
We demonstrate for the first time, to the best of our
knowledge, a simple blood test for cancer detection. This
test is based on the premise of exploiting the natural
tumor-homing ability of MSCs to further engineer them
to express a secreted luciferase with optimal biocompati-
bility and kinetic parameters. Similar to our current
murine studies, these “reporter MSCs” could be devel-
oped to identify the presence of small tumors or metas-
tases in humans that would otherwise be undetectable
by existing imaging modalities. We hope this simple “off
the shelf” allogeneic stem cell-based diagnostic test can
be used to screen, detect, and monitor cancer on a rou-
tine basis.Additional files
Additional file 1: Figure S1. Firefly and humanized Gaussia luciferases
are substrate-specific and not cross-reactive. hGluc-MSCs, Fluc-tdT-MSCs
(Fluc-MSCs), and N-MSCs were seeded in 96-well plate. The firefly luciferase
substrate D-luciferin (final concentration = 150 μg/ml) or the humanized
Gaussia luciferase substrate CTZ (final concentration = 20 μM) was
added, and luciferase activity was measured with a plate reader. Error
bar: mean ± standard deviation. Exposure time = 2 s. A.U. arbitrary units,
CTZ coelenterazine, Fluc firefly luciferase, hGluc humanized Gaussia
luciferase, MSC mesenchymal stem cell, tdT tdTomato red fluorescent
protein. (PNG 37 kb)
Additional file 2: Figure S2. Engineered mesenchymal stem cells
(Fluc-tdT-MSCs) express firefly luciferase (Fluc) and red fluorescent
protein (tdT). (A) Fluc-tdT-MSCs (Fluc-MSCs) were seeded onto 96-well
plate, and 24 hours later D-luciferin was added at a final concentration
of 150 μg/ml. Fluc activity was measured with a plate reader. Error bar:
mean ± standard deviation. Exposure time = 2 s. ***P <0.001. (B-D)
Fluc-tdT-MSC were imaged by fluorescence microcopy 24 hours after
seeding. Scale bar: 50 μm. A.U. arbitrary units, MSC mesenchymal stem
cell, tdT tdTomato red fluorescent protein. (PNG 6051 kb)
Additional file 3: Figure S3. Systemically infused MSCs persist in the
lungs of the LoVo cancer cell-bearing mice. Five weeks after LoVo
colon cancer cells were seeded intravenously into NSG mice, 106
Fluc-tdT-MSCs were administered systemically into both tumor-free
(blue) and tumor-bearing (red) mice. Then mice were injected intraperi-
toneally with D-Luciferin (150 mg/kg in Dulbecco’s phosphate-buffered
saline), and in vivo Fluc activity was measured at different time points
(6, 24, and 48 hours and 7 and 10 days after MSC infusion) by using an
IVIS Lumina to begin data acquisition 10 minutes after substrate
administration (exposure time = 60 s). Fluc activity measured at different
time points was quantified. Similar to the results with MDA-MB-231
breast cancer cells, MSCs were cleared out faster in tumor-free mice,
showing that the tumor tropism of MSCs is applicable to multiple
types of cancers. Error bar: mean ± standard error of the mean. *P <0.05.
n=4 for tumor-bearing mice and n=3 for tumor-free mice. Fluc firefly
luciferase, MSC mesenchymal stem cell, NSG nonobese diabetic/severe
combined immunodeficiency gamma, tdT tdTomato red fluorescent
protein. (PNG 128 kb)
Additional file 4: Figure S4. Engineered mesenchymal stem cell
(hGluc-MSC) infusion has no influence on the growth of cancer metastasis
size in vivo. Five weeks after Fluc-tdT-231 were seeded intravenously into
NSG mice, 106 hGluc-MSCs or PBS was administered systemically into
tumor-bearing mice (day 0). In vivo Fluc activity was measured with IVIS
Lumina 10 minutes after substrate administration before (day 0) and
10 days after MSC infusion (day 10). Exposure time = 5 s. Relative metastasis
index (RMI) = Luciferase activity on day 10 (after) / Luciferase activity on day
0 (before). N=4 for each group. hGluc humanized Gaussia luciferase, MSC
mesenchymal stem cell, n.s. not significant, NSG nonobese diabetic/severe
combined immunodeficiency gamma, PBS phosphate-buffered saline, tdT
tdTomato red fluorescent protein. (PNG 126 kb)Abbreviations
ATCC: American Type Culture Collection; BRCA1/2: Breast cancer 1/2;
CM: Conditioned medium; CT: Computed tomography; CTZ: Coelenterazine;
CXCL12: C-X-C motif chemokine 12; DPBS: Dulbecco’s phosphate-buffered
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fluorescent protein; EPR: Enhanced permeability and retention; FBS: Fetal
bovine serum; Fluc: Firefly luciferase; hGluc: Humanized Gaussia luciferase;
i.p.: Intraperitoneal; i.v.: Intravenously; LV: Lentiviral; MRI: Magnetic resonance
imaging; MSC: Mesenchymal stem cell; NSG: Nonobese diabetic/severe
combined immunodeficiency gamma; PBS: Phosphate-buffered saline;
PenStrep: penicillin-streptomycin; PET: Positron emission tomography;
RFP: Red fluorescent protein; tdT: tdTomato red fluorescent protein;
UCI: University of California, Irvine.
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